Anaptysbio company information, Employees & Contact Information

Anaptys Announces Late-Breaking Oral Presentation of Complete Phase 2b Data for Rosnilimab in Rheumatoid Arthritis at Upcoming ACR Convergence 2025 Yahoo Finance

AnaptysBio Announces Late-Breaking Presentation of Phase 2b Trial Data for Rosnilimab in Rheumatoid Arthritis at ACR Convergence 2025 Quiver Quantitative

$2.7B Peak Sales Potential: AnaptysBio to Separate Jemperli Royalty Business from Drug Pipeline by 2026 Stock Titan

Investigational Rosnilimab Emerges as a Novel, Differentiated Treatment Option for Rheumatoid Arthritis Fierce Biotech

Anaptys Announces Intent to Separate Biopharma Operations from Substantial Royalty Assets by Year-end 2026 Yahoo Finance

Anaptys and Vanda Announce Global Licensing Agreement of Imsidolimab for GPP Dermatology Times

Novel CD122 Antagonist: AnaptysBio to Present Phase 1 Data for Celiac Disease Drug ANB033 Stock Titan

AnaptysBio Reports Positive Phase 2b Data for Rosnilimab in Rheumatoid Arthritis and Completes Enrollment for Ulcerative Colitis Trial Quiver Quantitative

Vanda Pharmaceuticals and Anaptys Announce Exclusive Global License Agreement for Vanda to Develop and Commercialize Imsidolimab, an IL-36R Antagonist PR Newswire

Anaptys to Announce Updated Data from Phase 2b Trial of Rosnilimab, a PD-1 Depleter and Agonist, for Rheumatoid Arthritis on June 3, 2025 The Manila Times

Anaptys to Present at the 43rd Annual J.P. Morgan Healthcare Conference | User | punxsutawneyspirit.com FinancialContent

Anaptys to Provide Overview of ANB033, a CD122 antagonist, at Virtual Investor Event on Tuesday, Oct. 14 Yahoo Finance

Biotech Firm AnaptysBio Announces Triple Conference Schedule: Cantor, Wells Fargo & Stifel Events in September Stock Titan

AnaptysBio to Host Investor Call for Phase 2b RENOIR Trial Data of Rosnilimab in Rheumatoid Arthritis Quiver Quantitative

6‑Month JAK‑like Efficacy: Anaptys' Rosnilimab Phase 2b Accepted for ACR Late‑Breaking Oral Presentation Stock Titan

AnaptysBio plans to split biotech and Jemperli royalties into separate businesses Fierce Biotech

Anaptys Announces First Quarter 2025 Financial Results and Provides Business Update Yahoo Finance

Anaptys Delivers Strong RA Trial Results and Eyes $75M Milestone as Pipeline Advances Stock Titan

Anaptys Announces Rosnilimab Achieved Positive Results in RA Phase 2b Trial and Highest Ever Reported CDAI LDA Response Over 6 Months Yahoo Finance

AnaptysBio Discontinues Investment In Eczema Candidate After Disappointing Data Yahoo Finance

AnaptysBio Announces Positive Topline Results from Phase 3 Trial of Imsidolimab for GPP Dermatology Times

AnaptysBio: Potential Promise, But Some Cause For Skepticism (NASDAQ:ANAB) Seeking Alpha

AnaptysBio Plans Business Split To Sharpen Focus on Asset Value BioSpace

AnaptysBio Releases Positive Top-Line Phase 3 Results of Imsidolimab for GPP Flares Dermatology Times

AnaptysBio splits operations into two companies (ANAB:NASDAQ) Seeking Alpha

AnaptysBio’s atopic dermatitis trial of BTLA agonist misses endpoints Clinical Trials Arena

AnaptysBio rises on plans to split company The Pharma Letter

AnaptysBio: Positive RA Data Bodes Well For Continued Rosnilimab Advancement (NASDAQ:ANAB) Seeking Alpha

AnaptysBio: Rosnilimab's RA Data Sets The Stage For Blockbuster Potential (NASDAQ:ANAB) Seeking Alpha

AnaptysBio: Doubts About Cash And Upcoming Rheumatoid Arthritis Readout Seeking Alpha

AnaptysBio: An Immunology Pipeline-In-A-Pill Company Worth Watching Seeking Alpha

AnaptysBio's PD-1 drug reduces rheumatoid arthritis in phase 2 trial Fierce Biotech

AnaptysBio Stock Rise: Analyzing Latest Developments timothysykes.com

AnaptysBio rockets on rosnilimab data The Pharma Letter

D.C. biotech Vanda Pharmaceuticals acquires AnaptysBio’s drug for rare skin disorder The Business Journals

United Natural Foods Posts Upbeat Results, Joins AnaptysBio, Semtech, UiPath And Other Big Stocks Moving Higher On Tuesday Benzinga

AnaptysBio Stock Gets A Price Target Hike After Announcing Plan To Separate Royalty, Biopharma Businesses – Check Out The New Level Stocktwits

Top Biotech Catapults Higher As Sanofi Takes A Stake Investor's Business Daily

Intuitive Machines Posts Q4 Results, Joins Tesla, AnaptysBio, Coherent And Other Big Stocks Moving Higher On Monday Benzinga

Why targeting BTLA, a novel checkpoint receptor, may be key to treating an overactive immune system statnews.com

AnaptysBio shares collapse after ‘worst case scenario’ for key drug BioPharma Dive

Imsidolimab Gets Orphan Drug Designation for Generalized Pustular Psoriasis Medical Professionals Reference

AnaptysBio's IL-33 antibody stumbles in midphase eczema trial Fierce Biotech

ANAB Stock Price and Chart — NASDAQ:ANAB TradingView

Coupling mammalian cell surface display with somatic hypermutation for the discovery and maturation of human antibodies PNAS

FierceBiotech's 2013 Fierce 15 Fierce Biotech